BioCentury Hot Topics

The Trump administration and Congress are moving quickly to disrupt the federal government. Biopharma leaders need inside information and reliable analyses to navigate the rapidly evolving environment and distinguish between noise and actionable information.

From the origins of the orphan drug industry to recent initiatives to expand and accelerate drug development for rare diseases

With the first wave of GLP-1 therapies poised to become the biggest blockbusters in biopharma history, the focus turns to what's next in obesity, including combination therapies and new mechanisms to address an improved quality and duration of weight loss and co-morbidities

The era of human-first discovery is here, and it’s colliding with big data and new analytical tools to create an imperative to ensure drug targets play a causal role in disease. Illuminating causal human biology is the goal. How to accomplish this is the question.

BioCentury documents the approval of new modality therapies in a complimentary chart suitable for printing and display, or incorporation into a presentation

BioCentury’s deep dive into U.S.-China life sciences public policy, from the Biosecure Act to executive orders. BioCentury’s reporting brings readers inside Congress and the White House as legislators and government officials seek to balance national security, commercial competition, privacy and geopolitical rivalry.

BioCentury's deep dive into the law, exploring its impacts, explaining how the choices the federal government is making in implementing it, and options for medical product developers as they navigate the new landscape

A new era of causal biology, improved drug delivery, and biomarker-based decision-making has injected renewed optimism into neurology drug development. The question now is which indications and target spaces will see these factors align to drive meaningful progress.

Regardless of how macroeconomic factors influence the ups and downs of the public market, both public and private biotechs have a near constant need to raise capital when its available to finance the development of their pipelines and technologies.